胸部放疗后18F-FES-PET/CT肺部非肿瘤摄取增强:与纤维化相关?
该回顾性描述性研究分析了2008至2017年108例18F-FES-PET/CT扫描,比较胸部放疗后与未放疗患者肺部非肿瘤FES摄取增强的发生率。结果显示放疗组为56%(39/70),未放疗组为24%(9/38);有增强摄取者中纤维化占77%(37/48),无增强摄取者中占25%(15/60),p<0.001。结论提示放疗后肺部非肿瘤FES摄取增强应与转移鉴别,并考虑放疗史或肺纤维化病史。
要点
- 胸部放疗后患者肺部非肿瘤FES摄取增强发生率为56%(39/70)。
- 无胸部放疗患者肺部非肿瘤FES摄取增强发生率为24%(9/38)。
- 有增强摄取者纤维化占77%(37/48),无增强摄取者占25%(15/60)。
核心结论
- 胸部放疗后,相当比例患者可在放疗野内出现FES-PET非肿瘤摄取增强,且似与纤维化相关。
- 发现肺部FES摄取增强时不应解读为转移,应结合近期放疗史或肺纤维化病史。
研究设计与样本
- 回顾性描述性研究,分析本机构2008至2017年全部FES-PET/CT扫描。
- 比较胸部放疗后患者与从未胸部放疗患者的扫描,共108例(放疗组70例,未放疗组38例)。
- 主要结局为肺部非肿瘤FES摄取增强,定义为视觉上FES摄取增高且同期增强CT无肿瘤病变。
主要发现
- 放疗组肺部非肿瘤FES摄取增强39/70(56%),未放疗组9/38(24%)。
- 有增强摄取者中纤维化37/48(77%),无增强摄取者中纤维化15/60(25%),p<0.001。
临床怎么用
- 解读肺部FES-PET摄取增强时,需考虑胸部放疗史及肺纤维化可能,避免误判为转移。
- 报告时应结合近期放疗信息或肺纤维化病史综合判断。
局限性
- 回顾性描述性研究,样本量有限(共108例扫描)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The use of 16α-[18F]fluoro-17β-estradiol (FES) positron emission tomography (PET) in clinical dilemmas and for therapy decision-making in lesions expressing estrogen receptors is growing. However, on a considerable number of FES PET scans, previously performed in a research and clinical setting in our institution, FES uptake was noticed in the lungs without an oncologic substrate. We hypothesized that this uptake was related to pulmonary fibrosis as a result of radiation therapy. This descriptive study therefore aimed to investigate whether radiation therapy in the thoracic area is possibly related to enhanced pulmonary, non-tumor FES uptake. METHODS: All FES-PET/CT scans performed in our institution from 2008 to 2017 were retrospectively analyzed. Scans from patients who had received irradiation in the thoracic area prior to the scan were compared to scans of patients who had never received irradiation in the thoracic area. The primary outcome was the presence of enhanced non-tumor FES uptake in the lungs, defined as visually increased FES uptake in the absence of an oncologic substrate on the concordant (contrast-enhanced) CT scan. All CT scans were evaluated for the presence of fibrosis or oncologic substrates. RESULTS: A total of 108 scans were analyzed: 70 scans of patients with previous irradiation in the thoracic area and 38 of patients without. Enhanced non-tumor FES uptake in the lungs was observed in 39/70 irradiated patients (56%), versus in 9/38 (24%) of non-irradiated patients. Fibrosis was present in 37 of the 48 patients with enhanced non-tumor FES uptake (77%), versus in 15 out of 60 (25%) patients without enhanced non-tumor uptake, irrespective of radiotherapy (p < 0.001). CONCLUSION: After irradiation of the thorax, enhanced non-tumor uptake on FES-PET can be observed in the radiation field in a significant proportion of patients. This seems to be related to fibrosis. When observing enhanced FES uptake in the lungs, this should not be interpreted as metastases. Information on recent radiation therapy or history of pulmonary fibrosis should therefore be taken into consideration.
引用
- Venema CM, de Vries EFJ, van der Veen SJ, et al. Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis? EJNMMI Res. 2019. PMID: 31444658. doi:10.1186/s13550-019-0549-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。